United Therapeutics Corp - UTHR Net earnings per one share for the last twelve months

United Therapeutics Corp (UTHR) - corporate logo

United Therapeutics dominates the pulmonary hypertension therapy niche, effectively blocking generic expansion. The annual EPS growth rate over the last 12 months helps assess current profit dynamics, where 0.30 reflects the latest value of the metric. Growth is based on exclusive patents and strict FDA control. Visionary Martin Rothblat is developing innovative drug delivery methods and xenotransplantation.

UTHR: unither.com Net earnings per share for the last 12 months 02/11/2024 - 11/18/2026

United Therapeutics - analytical breakdowns and key metrics (UTHR)

Fundamental company valuation:UTHR - United Therapeutics Corp
Brand item of United Therapeutics Inc.

Investors are assessing the long-term sustainability of United Therapeutics (UTHR) through the lens of profit generation efficiency. This indicator measures the annual change in net income per share over a rolling period, revealing the gap between financial reporting and market value. By analyzing the 12-month YoY change in net income per share, one can determine the risk of overpaying for the asset. The stability of this metric confirms the success of costly developments in xenotransplantation and bioprinting.

Competitor analysis

Earnings per one share for the last 12 months VRTX|ALNY: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Insmed Inc (INSM)|BMRN (BioMarin) - Net earnings per share (EPS TTM)|Earnings per share for the last 12 months BBIO (BridgeBio)|Earnings per share for the last twelve months bgm.ltd (BGM)|COGT (Cogent Biosciences Inc) - Earnings per share for the trailing year|Earnings per share for the last twelve months Xeris Biopharma Holdings XERS|KROS (Keros Pharma) - Earnings per one share for the last 12 months|Arcturus Therapeutics - Net earnings per share (EPS TTM)|Earnings per share for the trailing year ETON (Eton Pharmaceuticals)|KMDA: Net earnings per share (EPS TTM)|Fulcrum Therapeutics Inc (FULC) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months abeonatherapeutics.com|MREO: Earnings per share for the trailing year|Net earnings per share (EPS TTM) PLX|Net earnings per share for the last 12 months Pliant Therapeutics, Inc. PLRX|Net earnings per share (EPS TTM) APLT (Applied Therapeutics Inc.)|Net earnings per share (EPS TTM) Rein Therapeutics Inc. RNTX|gelteq.com - Net earnings per share (EPS TTM)|AYTU - Net earnings per share (EPS TTM)|CMMB: Net earnings per share (EPS TTM)|SRx Health Solutions Inc. - Earnings per share for the trailing year|Earnings per share for the last twelve months Polyrizon Ltd|AEZS (Aeterna Zentaris) - Earnings per share for the last four quarters|Earnings per share for the last twelve months CTD Holdings (CYTH)|INZY: Earnings per one share for the last 12 months|Earnings per share for the last twelve months Reneo Pharmaceuticals Inc. RPHM|Net earnings per share for the last four quarters COSCIENS Biopharma Inc. (CSCI)